EcoDrugPlus

Toll Like Receptor 2

Ensembl ID : ENSBTAG00000008008
Gene Symbol: TLR2
3 Enzyme and pathways 5 Cross references
261 Possible Orthologues:

Toll Like Receptor 4

Ensembl ID : ENSBTAG00000006240
Gene Symbol: TLR4
23 Enzyme and pathways 5 Cross references
139 Possible Orthologues:

Toll Like Receptor 7

Ensembl ID : ENSBTAG00000022161
Gene Symbol: TLR7
5 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Toll Like Receptor 9

Ensembl ID : ENSBTAG00000018198
Gene Symbol: TLR9
14 Enzyme and pathways 5 Cross references
94 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSBTAG00000037718
Gene Symbol: TAAR1
7 Enzyme and pathways 5 Cross references
611 Possible Orthologues:

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSBTAG00000018035
Gene Symbol: TGFBR1
10 Enzyme and pathways 5 Cross references
248 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSBTAG00000002062
Gene Symbol: TRPA1
4 Enzyme and pathways 5 Cross references
240 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSBTAG00000014652
Gene Symbol: TRPM8
4 Enzyme and pathways 5 Cross references
170 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSBTAG00000018880
Gene Symbol: TRPV1
4 Enzyme and pathways 5 Cross references
146 Possible Orthologues:

Translocator Protein

Ensembl ID : ENSBTAG00000018073
Gene Symbol: TSPO
5 Cross references
134 Possible Orthologues:

Transthyretin

Ensembl ID : ENSBTAG00000010991
Gene Symbol: TTR
10 Enzyme and pathways 5 Cross references
173 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSBTAG00000005343
Gene Symbol: TPH1
4 Enzyme and pathways 5 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).